Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.51 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.51 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 6/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25084816 | 0.87 | TGFBR1 (0.49) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL30156584 | 0.87 | TGFBR1 (0.49) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL25084764 | 0.80 | TGFBR1 (0.43) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL23408258 | 0.80 | TGFBR1 (0.44) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL23408259 | 0.79 | TGFBR1 (0.55) | TGFBR1TGFBR2MAP3K20CYP2D6MAPK14 | |
| SCHEMBL29796457 | 0.76 | TGFBR1 (0.43) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL23389778 | 0.76 | TGFBR1 (0.43) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL24311950 | 0.71 | TGFBR1 (0.62) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL30155878 | 0.71 | TGFBR1 (0.39) | TGFBR1TGFBR2MAP3K20CYP2D6THRB | |
| SCHEMBL408963 | 0.71 | TGFBR1 (0.69) | TGFBR1TGFBR2MAP3K20CYP2D6THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021102468-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | WO | disclosed |